These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 8895780)

  • 41. Immunological crossreactivity between the class I epitope of streptococcal M protein and myosin.
    Cunningham MW; Quinn A
    Adv Exp Med Biol; 1997; 418():887-92. PubMed ID: 9331792
    [No Abstract]   [Full Text] [Related]  

  • 42. Superantigens of group A streptococci (Streptococcus pyogenes). Distribution, induction of antibodies, and binding to human cell types.
    Wagner B; Gerlach D; Ozegowski JH; Wagner M
    Adv Exp Med Biol; 1997; 418():555-7. PubMed ID: 9331712
    [No Abstract]   [Full Text] [Related]  

  • 43. Determination of group a streptococcal anti-M type-specific antibody in sera of rheumatic fever patients after 45 years.
    Bencivenga JF; Johnson DR; Kaplan EL
    Clin Infect Dis; 2009 Oct; 49(8):1237-9. PubMed ID: 19761409
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Don't forget about Streptococcus pyogenes! (comment on Microbes Infect. 5 (2003) 1329-1335).
    Collin M
    Microbes Infect; 2004 Mar; 6(3):336; author reply 337. PubMed ID: 15026018
    [No Abstract]   [Full Text] [Related]  

  • 45. Differences among group A streptococcus epidemiological landscapes: consequences for M protein-based vaccines?
    Smeesters PR; McMillan DJ; Sriprakash KS; Georgousakis MM
    Expert Rev Vaccines; 2009 Dec; 8(12):1705-20. PubMed ID: 19905872
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The future streptococcal M. vaccine against rheumatic fever.
    Imran M; Jan A
    J Pak Med Assoc; 1988 Jul; 38(7):176-7. PubMed ID: 3149682
    [No Abstract]   [Full Text] [Related]  

  • 47. A two-domain mechanism for group A streptococcal adherence through protein F to the extracellular matrix.
    Ozeri V; Tovi A; Burstein I; Natanson-Yaron S; Caparon MG; Yamada KM; Akiyama SK; Vlodavsky I; Hanski E
    EMBO J; 1996 Mar; 15(5):989-98. PubMed ID: 8605894
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Acquisition of group A streptococcal M protein antibodies.
    Quinn RW; Vander Zwaag R; Lowry PN
    Pediatr Infect Dis; 1985; 4(4):374-8. PubMed ID: 3895177
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Streptococcal immunology: protection versus injury.
    Stollerman GH
    Ann Intern Med; 1978 Mar; 88(3):422-3. PubMed ID: 343684
    [No Abstract]   [Full Text] [Related]  

  • 50. Role of M protein in adherence of group A streptococci.
    Caparon MG; Stephens DS; Olsén A; Scott JR
    Infect Immun; 1991 May; 59(5):1811-7. PubMed ID: 2019444
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Streptococcal defenses against host immune attack: the M protein-fibrinogen interaction.
    Whitnack E; Dale JB; Beachey EH
    Trans Assoc Am Physicians; 1983; 96():197-202. PubMed ID: 6208666
    [No Abstract]   [Full Text] [Related]  

  • 52. Correlates of Protection for M Protein-Based Vaccines against Group A Streptococcus.
    Tsoi SK; Smeesters PR; Frost HR; Licciardi P; Steer AC
    J Immunol Res; 2015; 2015():167089. PubMed ID: 26101780
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Identification of the domains of the fibronectin-binding protein I of Streptococcus pyogenes responsible for adjuvanticity.
    Schulze K; Guzmán CA
    FEMS Immunol Med Microbiol; 2003 Jul; 37(2-3):173-7. PubMed ID: 12832122
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Protective immunity against Streptococcus pyogenes challenge in mice after immunization with fibronectin-binding protein.
    Terao Y; Okamoto S; Kataoka K; Hamada S; Kawabata S
    J Infect Dis; 2005 Dec; 192(12):2081-91. PubMed ID: 16288371
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Human secretory immune response to streptococcal M protein. Identification of a secretory IgA epitope in the exposed conserved region.
    Yoshinaga M; Miyata K; Fischetti VA
    Adv Exp Med Biol; 1997; 418():913-5. PubMed ID: 9331797
    [No Abstract]   [Full Text] [Related]  

  • 56. New multi-determinant strategy for a group A streptococcal vaccine designed for the Australian Aboriginal population.
    Brandt ER; Sriprakash KS; Hobb RI; Hayman WA; Zeng W; Batzloff MR; Jackson DC; Good MF
    Nat Med; 2000 Apr; 6(4):455-9. PubMed ID: 10742155
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [Distribution of type-specific antibodies to streptococcal lipoproteinase based on population screening data].
    Benevolenskaia LI; Iontova IM; Burlev AA; Totolian AA
    Zh Mikrobiol Epidemiol Immunobiol; 1986 Sep; (9):61-6. PubMed ID: 3538728
    [TBL] [Abstract][Full Text] [Related]  

  • 58. [OF- and anti-OF test systems in microbiological and epidemiologic practice].
    Beliakova IV; Totolian AA
    Vestn Akad Med Nauk SSSR; 1989; (11):54-9. PubMed ID: 2483011
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Protein adhesins as vaccine antigens for Group A Streptococcus.
    Raynes JM; Young PG; Proft T; Williamson DA; Baker EN; Moreland NJ
    Pathog Dis; 2018 Mar; 76(2):. PubMed ID: 29718270
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Binding of C1q to group A streptococcal M-family proteins.
    Koroleva IV; Schalen C; Sjoholm A
    Adv Exp Med Biol; 1997; 418():581-3. PubMed ID: 9331718
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.